Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

780 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab.
Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Fujimura T, Yamamoto Y, Hata H, Gosho M, Tanaka R, Yamaguchi K, Nonomura Y, Hirai I, Furudate S, Okuhira H, Imafuku K, Aoki M, Matsushita S. Fujisawa Y, et al. Among authors: otsuka a. J Dermatol Sci. 2017 Nov;88(2):225-231. doi: 10.1016/j.jdermsci.2017.07.007. Epub 2017 Jul 16. J Dermatol Sci. 2017. PMID: 28736218
Vascular endothelial growth factor partially induces pruritus via epidermal hyperinnervation in imiquimod-induced psoriasiform dermatitis in mice.
Wong LS, Otsuka A, Yamamoto Y, Nonomura Y, Nakashima C, Honda T, Dainichi T, Kitoh A, Nakajima S, Hirakawa S, Miyachi Y, Kabashima K. Wong LS, et al. Among authors: otsuka a. J Dermatol Sci. 2016 Aug;83(2):148-51. doi: 10.1016/j.jdermsci.2016.04.008. Epub 2016 Apr 30. J Dermatol Sci. 2016. PMID: 27156794 No abstract available.
Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-α is a biomarker of nivolumab recativity.
Tanaka R, Okiyama N, Okune M, Ishitsuka Y, Watanabe R, Furuta J, Ohtsuka M, Otsuka A, Maruyama H, Fujisawa Y, Fujimoto M. Tanaka R, et al. Among authors: otsuka a. J Dermatol Sci. 2017 Apr;86(1):71-73. doi: 10.1016/j.jdermsci.2016.12.019. Epub 2016 Dec 29. J Dermatol Sci. 2017. PMID: 28069323 No abstract available.
Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients.
Nonomura Y, Otsuka A, Nakashima C, Seidel JA, Kitoh A, Dainichi T, Nakajima S, Sawada Y, Matsushita S, Aoki M, Takenouchi T, Fujimura T, Hatta N, Koreeda S, Fukushima S, Honda T, Kabashima K. Nonomura Y, et al. Among authors: otsuka a. Oncoimmunology. 2016 Oct 18;5(12):e1248327. doi: 10.1080/2162402X.2016.1248327. eCollection 2016. Oncoimmunology. 2016. PMID: 28123885 Free PMC article.
Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma.
Honda Y, Otsuka A, Ono S, Yamamoto Y, Seidel JA, Morita S, Hirata M, Kataoka TR, Takenouchi T, Fujii K, Kanekura T, Okubo Y, Takahashi K, Yanagi T, Hoshina D, Hata H, Abe R, Fujimura T, Funakoshi T, Yoshino K, Masuzawa M, Amoh Y, Tanaka R, Fujisawa Y, Honda T, Kabashima K. Honda Y, et al. Among authors: otsuka a. Oncoimmunology. 2016 Nov 4;6(1):e1253657. doi: 10.1080/2162402X.2016.1253657. eCollection 2017. Oncoimmunology. 2016. PMID: 28197370 Free PMC article.
780 results